We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
Read MoreHide Full Article
Bio-Techne (TECH - Free Report) reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks Consensus Estimate by 10.5%. The bottom line improved from the year-ago figure of 40 cents.
The quarter's adjustments eliminated the impact of certain one-time items, including amortization of intangibles, amortization of Wilson Wolf intangible assets and acquired inventory and restructuring and restructuring-related costs among others.
GAAP EPS was 22 cents compared with 17 cents in the prior-year quarter.
Following the earnings announcement, shares of TECH rose 4.8% in pre-market trading today.
TECH's Q2 Revenues in Detail
Bio-Techne registered net sales of $297.0 million, up 9% year over year on a reported basis and 9% on an organic basis. The figure also topped the Zacks Consensus Estimate by 4.1%.
Quarter in Details
The company reports under two business segments — Protein Sciences and Diagnostics and Genomics.
Within Protein Sciences, Bio-Techne recorded revenues of $211.6 million, up 7% year over year (up 8% organically). As of Dec. 31, 2023, a business within the Protein Sciences Segment met the criteria as held-for-sale. This business has been excluded from the segment's fiscal 2025 operating results. This exclusion reduced total sales by 1%.
Within Diagnostics and Genomics, sales improved 12% to $84.1 million (up 12% organically as well) in the fiscal second quarter.
Margin Trend
Bio-Techne’s gross profit edged up 9.8% to $193.9 million. Gross margin expanded 50 basis points (bps) to 65.3% despite a 7.4% rise in cost of sales.
Selling, general and administrative expenses escalated 5% to $121.4 million. Research and development expenses totaled $25 million, up 9.2% year over year. Total operating expenses were $146.5 million, up 5.7% from the prior-year quarter’s level.
Operating margin expanded a huge 202 bps to 16% in the reported quarter.
Capital Structure
Bio-Techne exited the fiscal second quarter with cash and equivalents and short-term available-for-sale investments of $177.5 million compared with $152.9 million at the end of the first quarter of fiscal 2025. Long-term debt obligations totaled $300 million at the end of the reported quarter compared with $319 million at the end of the fiscal first quarter.
Cumulative net cash provided by operating activities was $148.2 million at the end of the second quarter compared with $142.5 million a year ago.
Bio-Techne’s second-quarter fiscal 2025 adjusted earnings and revenues exceeded the respective Zacks Consensus Estimate. The company registered a year-over-year improvement in organic sales for both segments. Additionally, expanding margins look encouraging.
According to Bio-Techne’s management, the start of fiscal 2025 was largely consistent with the company’s expectations. During the quarter, the company experienced improvement in the biopharma end-market. This was augmented by the strong results of its cell and gene therapy business, including robust growth in the GMP reagent portfolio.
TECH's Zacks Rank and Key Picks
Bio-Techne currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Quest Diagnostics (DGX - Free Report) , ResMed (RMD - Free Report) and Cardinal Health (CAH - Free Report) .
Quest Diagnostics reported fourth-quarter 2024 adjusted EPS of $2.23, which topped the Zacks Consensus Estimate by 1.8%. Revenues of $2.62 billion beat the Zacks Consensus Estimate by 1.9%. DGX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DGX has an earnings yield of 5.9% compared with the industry’s 4.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 3.8%.
ResMed, carrying a Zacks Rank #2 at present, posted second-quarter fiscal 2025 adjusted EPS of $2.43, which topped the Zacks Consensus Estimate by 5.6%. Revenues of $1.28 billion exceeded the Zacks Consensus Estimate by 1.6%.
RMD has an estimated fiscal 2025 earnings growth rate of 21.9% compared with the industry’s 13.2%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.9%.
Cardinal Health, carrying a Zacks Rank #2 at present, posted second-quarter fiscal 2025 adjusted EPS of $1.93, which outpaced the Zacks Consensus Estimate by 10.3%. Revenues of $55.26 billion exceeded the Zacks Consensus Estimate by 0.7%.
CAH has an estimated five-year earnings growth rate of 10.7% compared with the industry’s 9.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
Bio-Techne (TECH - Free Report) reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks Consensus Estimate by 10.5%. The bottom line improved from the year-ago figure of 40 cents.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
The quarter's adjustments eliminated the impact of certain one-time items, including amortization of intangibles, amortization of Wilson Wolf intangible assets and acquired inventory and restructuring and restructuring-related costs among others.
GAAP EPS was 22 cents compared with 17 cents in the prior-year quarter.
Following the earnings announcement, shares of TECH rose 4.8% in pre-market trading today.
TECH's Q2 Revenues in Detail
Bio-Techne registered net sales of $297.0 million, up 9% year over year on a reported basis and 9% on an organic basis. The figure also topped the Zacks Consensus Estimate by 4.1%.
Quarter in Details
The company reports under two business segments — Protein Sciences and Diagnostics and Genomics.
Within Protein Sciences, Bio-Techne recorded revenues of $211.6 million, up 7% year over year (up 8% organically). As of Dec. 31, 2023, a business within the Protein Sciences Segment met the criteria as held-for-sale. This business has been excluded from the segment's fiscal 2025 operating results. This exclusion reduced total sales by 1%.
Within Diagnostics and Genomics, sales improved 12% to $84.1 million (up 12% organically as well) in the fiscal second quarter.
Margin Trend
Bio-Techne’s gross profit edged up 9.8% to $193.9 million. Gross margin expanded 50 basis points (bps) to 65.3% despite a 7.4% rise in cost of sales.
Selling, general and administrative expenses escalated 5% to $121.4 million. Research and development expenses totaled $25 million, up 9.2% year over year. Total operating expenses were $146.5 million, up 5.7% from the prior-year quarter’s level.
Operating margin expanded a huge 202 bps to 16% in the reported quarter.
Capital Structure
Bio-Techne exited the fiscal second quarter with cash and equivalents and short-term available-for-sale investments of $177.5 million compared with $152.9 million at the end of the first quarter of fiscal 2025. Long-term debt obligations totaled $300 million at the end of the reported quarter compared with $319 million at the end of the fiscal first quarter.
Cumulative net cash provided by operating activities was $148.2 million at the end of the second quarter compared with $142.5 million a year ago.
Bio-Techne Corp Price, Consensus and EPS Surprise
Bio-Techne Corp price-consensus-eps-surprise-chart | Bio-Techne Corp Quote
Our Take on Bio-Techne
Bio-Techne’s second-quarter fiscal 2025 adjusted earnings and revenues exceeded the respective Zacks Consensus Estimate. The company registered a year-over-year improvement in organic sales for both segments. Additionally, expanding margins look encouraging.
According to Bio-Techne’s management, the start of fiscal 2025 was largely consistent with the company’s expectations. During the quarter, the company experienced improvement in the biopharma end-market. This was augmented by the strong results of its cell and gene therapy business, including robust growth in the GMP reagent portfolio.
TECH's Zacks Rank and Key Picks
Bio-Techne currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Quest Diagnostics (DGX - Free Report) , ResMed (RMD - Free Report) and Cardinal Health (CAH - Free Report) .
Quest Diagnostics reported fourth-quarter 2024 adjusted EPS of $2.23, which topped the Zacks Consensus Estimate by 1.8%. Revenues of $2.62 billion beat the Zacks Consensus Estimate by 1.9%. DGX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DGX has an earnings yield of 5.9% compared with the industry’s 4.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 3.8%.
ResMed, carrying a Zacks Rank #2 at present, posted second-quarter fiscal 2025 adjusted EPS of $2.43, which topped the Zacks Consensus Estimate by 5.6%. Revenues of $1.28 billion exceeded the Zacks Consensus Estimate by 1.6%.
RMD has an estimated fiscal 2025 earnings growth rate of 21.9% compared with the industry’s 13.2%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.9%.
Cardinal Health, carrying a Zacks Rank #2 at present, posted second-quarter fiscal 2025 adjusted EPS of $1.93, which outpaced the Zacks Consensus Estimate by 10.3%. Revenues of $55.26 billion exceeded the Zacks Consensus Estimate by 0.7%.
CAH has an estimated five-year earnings growth rate of 10.7% compared with the industry’s 9.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%.